Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer
Cancer Medicine · 2024
DOI: 10.1002/cam4.7395 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Junpei Yamaguchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplastic Stem Cells, Pancreatic Neoplasms, Trefoil Factor-1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background and Aims Pancreatic cancer is one of the most lethal malignancies, partly due to resistance to conventional chemotherapy. The chemoresistance of malignant tumors is associated with epithelial‐mesenchymal transition (EMT) and the stemness of cancer cells. The aim of this study is to investigate the availability and functional mechanisms of trefoil factor family 1 (TFF1), a tumor‐suppressive protein in pancreatic carcinogenesis, to treat pancreatic cancer.
Methods
To investigate the role of endogenous TFF1 in human and mice, specimens of human pancreatic cancer and genetically engineered mouse model of pancreatic cancer (KPC/TFF1KO; Pdx1‐Cre/LSL‐KRAS G12D /LSL‐p53 R172H /TFF1 −/− ) were analyzed by immunohistochemistry (IHC). To explore the efficacy of extracellular administration of TFF1, recombinant and chemically synthesized TFF1 were administered to pancreatic cancer cell lines, a xenograft mouse model and a transgenic mouse model.
Results
The deficiency of TFF1 was associated with increased EMT of cancer cells in mouse models of pancreatic cancer, KPC. The expression of TFF1 in cancer cells was associated with better survival rate of the patients who underwent chemotherapy, and loss of TFF1 deteriorated the benefit of gemcitabine in KPC mice. Extracellular administration of TFF1 inhibited gemcitabine‐induced EMT, Wnt pathway activation and cancer stemness, eventually increased apoptosis of pancreatic cancer cells in vitro. In vivo, combined treatment of gemcitabine and subcutaneous administration of TFF1 arrested tumor growth in xenograft mouse model and resulted in the better survival of KPC mice by inhibiting EMT and cancer stemness.
Conclusion
These results indicate that TFF1 can contribute to establishing a novel strategy to treat pancreatic cancer patients by enhancing chemosensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Institute of Transformative Bio-Molecules, Nagoya University, Nagoya, Japan.
ORCID-Profile: Junpei Yamaguchi, Toshio Kokuryo
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yamaguchi, J., Kokuryo, T., Yokoyama, Y., Oishi, S., Sunagawa, M., Mizuno, T., Onoe, S., Watanabe, N., Ogura, A., & Ebata, T. (2024). Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Cancer Medicine. https://doi.org/10.1002/cam4.7395
Vancouver
Yamaguchi J, Kokuryo T, Yokoyama Y, Oishi S, Sunagawa M, Mizuno T, et al. Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer. Cancer Medicine. 2024. doi:10.1002/cam4.7395
BibTeX
@article{Yamaguchi2024,
author = {Yamaguchi, Junpei and Kokuryo, Toshio and Yokoyama, Yukihiro and Oishi, Shunsuke and Sunagawa, Masaki and Mizuno, Takashi and Onoe, Shunsuke and Watanabe, Nobuyuki and Ogura, Atsushi and Ebata, Tomoki},
title = {Trefoil factor 1 suppresses stemness and enhances chemosensitivity of pancreatic cancer},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.7395}
}
EUVIMED